Epizyme Has Aggressive Plans For Accelerated Approval For Tazemetostat
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech is developing its EZH2 inhibitor in multi-arm Phase II studies in various forms of non-Hodgkin lymphoma as well as genetically defined solid tumors.